Optimizing Outpatient Serial Sputum Colony Counting for Studies of Tuberculosis Treatment in Resource-Poor Settings
Open Access
- 1 July 2012
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 50 (7) , 2315-2320
Abstract
Serial Sputum Colony Counting (SSCC) is an important technique in clinical trials of new treatments for tuberculosis (TB). Quantitative cultures on selective Middlebrook agar are used to calculate the rate of bacillary elimination from sputum collected from patients at different time points during the first 2 months of therapy. However, the procedure can be complicated by high sample contamination rates. This study, conducted in a resource-poor setting in Malawi, assessed the ability of different antifungal drugs in selective agar to reduce contamination. Overall, 229 samples were studied and 15% to 27% were contaminated. Fungal organisms were particularly implicated, and samples collected later in treatment were at particular risk ( P < 0.001). Amphotericin B (AmB) is the standard antifungal drug used on SSCC plates at a concentration of 10 mg/ml. On selective Middlebrook 7H10 plates, AmB at 30 mg/ml reduced sample contamination by 17% compared with AmB at 10 mg/ml. The relative risk of contamination using AmB at 10 mg/ml was 1.79 (95% confidence interval [CI], 1.25 to 3.55). On Middlebrook 7H11 plates, a combination of AmB at 10 mg/ml and carbendazim at 50 mg/ml was associated with 10% less contamination than AmB at 30 mg/ml. The relative risk of contamination with AmB at 30 mg/ml was 1.79 (95% CI, 1.01 to 3.17). Improved antifungal activity was accompanied by a small reduction in bacillary counts, but this did not affect modeling of bacillary elimination. In conclusion, a combination of AmB and carbendazim optimized the antifungal activity of selective media for growth of TB. We recommend this method to reduce contamination rates and improve SSCC studies in African countries where the burden of TB is highest.Keywords
This publication has 19 references indexed in Scilit:
- Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trialThe Lancet, 2009
- Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary TuberculosisAntimicrobial Agents and Chemotherapy, 2008
- Tuberculosis Diagnosis and Multidrug Resistance Testing by Direct Sputum Culture in Selective Broth without Decontamination or CentrifugationJournal of Clinical Microbiology, 2008
- Use of Nonlinear Mixed-Effects Analysis for Improved Precision of Early Pharmacodynamic Measures in Tuberculosis TreatmentAntimicrobial Agents and Chemotherapy, 2006
- Prospects for Advancing Tuberculosis Control Efforts through Novel TherapiesPLOS Medicine, 2006
- Clinical development of anti-tuberculosis drugsJournal of Antimicrobial Chemotherapy, 2006
- Optimal sampling strategies for early pharmacodynamic measures in tuberculosisJournal of Antimicrobial Chemotherapy, 2006
- Randomized Controlled Trial of a Drug Regimen That Includes Ciproftoxacin for the Treatment of Pulmonary TuberculosisClinical Infectious Diseases, 1996
- Selective media in the isolation of tubercle bacilli from tissuesJournal of Clinical Pathology, 1973
- A Selective Oleic Acid Albumin Agar Medium For Tubercle BacilliJournal of Medical Microbiology, 1972